FENDRR and chronic myelogenous leukemia, BCR-ABL1 positive: These findings also suggested foetal-lethal non-coding developmental regulatory RNA (FENDRR) as a potential target to reverse Adriamycin resistance and enhance therapeutic effectiveness in CML.